About PharmaReview
PharmaReview is a company based in London (United Kingdom) founded in 2011 by Tessa Pugh and Ralph Carter. The company has 34 employees as of December 31, 2020. PharmaReview offers products and services including Medical Copy Review Service and LMR Process Support. PharmaReview operates in a competitive market with competitors including Orphalan, NIMBLE Diagnostics, OneroRx, Nutrasource and Catalys Pacific, among others.
- Headquarter London, United Kingdom
- Employees 34 as on 31 Dec, 2020
- Founders Tessa Pugh, Ralph Carter
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pharmareview Limited
- Date of Incorporation 04 Oct, 2011
- Jurisdiction READING, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
$3.61 M (USD)57as on Dec 31, 2022
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
HHS
& 1 more
-
Employee Count
34
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PharmaReview
PharmaReview offers a comprehensive portfolio of products and services, including Medical Copy Review Service and LMR Process Support.
Provides review and approval of medical materials for compliance.
Assists with lead-up reviews and timely congress material handling.
People of PharmaReview
Unlock access to complete
Unlock access to complete
Funding Insights of PharmaReview
Investors in PharmaReview
PharmaReview has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS and Bridgepoint Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Middle-market businesses up to €1 billion are acquired pan-Europe.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for PharmaReview
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PharmaReview
Investment portfolio details for PharmaReview
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PharmaReview
Detailed financials for PharmaReview
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pharmareview Comparisons
Peer comparison for PharmaReview
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PharmaReview
PharmaReview operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orphalan, NIMBLE Diagnostics, OneroRx, Nutrasource and Catalys Pacific, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer and provider of access to innovative treatments to patients with rare diseases
|
|
| Locked | Locked | Locked |
Non-invasive diagnostic devices for cardiovascular stent monitoring are developed.
|
|
| Locked | Locked | Locked |
Telepharmacy services are delivered via an online platform for consultations.
|
|
| Locked | Locked | Locked |
Marketing services are provided for healthcare, nutraceutical, and pharmaceutical sectors.
|
|
| Locked | Locked | Locked |
Invests in biotech companies via global networks and partnerships for disease treatments.
|
Detailed competitors of PharmaReview
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pharmareview
Complete news archive for PharmaReview
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PharmaReview
PharmaReview was founded in 2011.
PharmaReview is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
As of Dec 31, 2020, the latest employee count at PharmaReview is 34.
PharmaReview was established in 2011 by co-founders Tessa Pugh and Ralph Carter in London, United Kingdom. Operations focus on delivering review services for pharmaceuticals within the life sciences sector. Expertise is applied to assess and evaluate drug-related processes, supporting industry compliance and development. The company maintains a presence in the UK, serving clients across related fields without extending into manufacturing or direct research.
PharmaReview's top competitors include Droplet, Orphalan and NIMBLE Diagnostics.
PharmaReview offers Medical Copy Review Service and LMR Process Support.
PharmaReview has 2 investors. Key investors include HHS, and Bridgepoint Capital.